Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: Experience at a single center and review of the literature

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 2, 2013, Pages 180-186

  Zavaglia, Claudio ^a   Airoldi, Aldo ^a   Mancuso, Andrea ^a   Vangeli, Marcello ^a   Viganò, Raffaella ^a   Cordone, Gabriella ^a   Gentiluomo, Maria ^a   Belli, Luca Saverio ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Everolimus; Hepatocellular carcinoma; Orthotopic liver transplantation; Sorafenib

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; HEPATITIS B ANTIBODY; NUCLEOSIDE DERIVATIVE; PREDNISOLONE; SORAFENIB; THYMOCYTE ANTIBODY;

ADULT; AGED; AMYLASE BLOOD LEVEL; ANOREXIA; ARTICLE; BACTERIAL INFECTION; BRAIN DISEASE; CANCER RECURRENCE; CHILD; CHOLESTASIS; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MALE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SKIN TOXICITY; VOMITING; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DRUG EVALUATION; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; RECURRENCE; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84872088341     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328359e550     Document Type: Article

References (42)

1. Zarrinpar A, Kaldas F, Busuttil RW. Liver transplantation for hepatocellular carcinoma: An update. Hepatobiliary Pancreat Dis Int 2011; 10:234-242
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699 (Pubitemid 26079803)
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236 (Pubitemid 43112690)
4. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis. Liver Transpl 2004; 10:534-540 (Pubitemid 38443593)
5. Hollebecque A, Decaens T, Boleslawski E, Mathurin P, Duvoux C, Pruvot FR, Dharancy S. Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation. Gastroenterol Clin Biol 2009; 33:361-369
6. Silva MF, Sherman M. Criteria for liver transplantation for HCC. J Hepatol 2011; 55:1137-1147
7. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: A review. Eur J Cancer 2004; 40:1474-1484 (Pubitemid 38757734)
8. Schwartz M, Roayaie S, Llovet J. How should patients with hepatocellular carcinoma after liver transplantation be treated? J Hepatol 2005; 43: 584-589 (Pubitemid 41253224)
9. Valdivieso A, Bustamante J, Gastaca M, Uriarte JG, Ventoso A, Ruiz P, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc 2010; 42:660-662
10. Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 2009; 100:1-8
11. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390
12. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol 2009; 10:25-34
13. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135:1972-1983
14. Treiber G. mTOR inhibitors for hepatocellular cancer: A forward-moving target. Expert Rev Anticancer Ther 2009; 9:247-261
15. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-1243
16. Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008; 40:3548-3553
17. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14:633-638 (Pubitemid 351696274)
18. Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, et al. Ras pathway activation in hepatocellular carcinoma and anti-Tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009; 51:725-733
19. Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2008; 14:5124-5130
20. Piguet AC, Saar B, Hlushchuk R, St-Pierre MV, McSheehy PM, Radojevic V, et al. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther 2011; 10:1007-1017
21. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655 (Pubitemid 13149996)
22. Cancer Therapy Evaluation Program, Common terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. 31 March 2003. Available at: Http://ctep.cancer.gov [Accessed 9 August 2006
23. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60
24. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698-711
25. Mancuso A, Airoldi A, ViganòR, Pinzello G. Fatal gastric bleeding during treatment for hepatocellular carcinoma recurrence after liver transplantation. Dig Liv Dis 2011; 43:754
26. Kim R, El-Gazzaz G, Tan A, Elson P, Byrne M, Chang YD, Aucejo F. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 2010; 79:62-66
27. Tan WF, Qiu ZQ, Yu Y, Ran RZ, Yi B, Lau WY, et al. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin 2010; 31: 1643-1648.
28. Li C, Zhang F, Zhang W, Zhang L, Huang Z, Wu P. Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. J Cancer Res Clin Oncol 2010; 136:1633-1640
29. Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 2010; 40:768-773
30. Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012; 18:45-52
31. Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, Düber C, et al. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Dig Liver Dis 2012; 44:432-437
32. Lee JO, Kim DY, Lim JH, Seo MD, Yi HG, Oh DY, et al. Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol 2009; 24:800-805
33. Yeganeh M, Finn RS, Saab S. Apparent Remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant 2009; 9:2851-2854
34. Bhoori S, Toffanin S, Sposito C, Germini A, Pellegrinelli A, Lampis A, Mazzaferro V. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle. J Hepatol 2010; 52:771-775
35. Wang Y, Speeg KV, Washburn WK, Halff G. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report. World J Gastroenterol 2010; 16:5518-5522
36. Waidmann O, Hofmann WP, Zeuzem S, Trojan J. mTOR inhibitors and sorafenib for recurrent hepatocellular carcinoma after orthotopic liver transplantation. J Hepatol 2011; 54:396-398
37. Kim R, Aucejo F. Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. J Gastrointest Cancer 2011; 42:50-53
38. Herden U, Fischer L, Schäfer H, Nashan B, von Baehr V, Sterneck M. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient. Transplantation 2010; 90:98-99
39. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-Analysis of clinical trials. Lancet Oncol 2009; 10:967-974
40. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116:2610-2621 (Pubitemid 44511625)
41. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-Term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-239
42. P̀ez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viňals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-231